There are no items in your cart
Add More
Add More
| Item Details | Price | ||
|---|---|---|---|
Introduction
Aaj Supriya Lifescience Ltd suddenly spotlight me aaya with sharp price jump aur strong intraday momentum. Aise moves normal nahi hote — jab kisi stock me sudden upside + volatility dikhti hai, wahan generally:
👉 Smart money activity hoti hai
👉 Pre-result positioning hoti hai
👉 Ya short-term momentum shift hota hai Is blog me hum samjhenge:
👉 Price jump kyu aaya
👉 Stock me kya chal raha hai
👉 Opportunity hai ya risk
Supriya Lifescience Ltd. supplies active pharmaceuticals ingredients (“APIs”), with a focus on research and development. Its products include 39 APIs focused diverse therapeutic segments such as anti-histamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. The company was founded by Satish Waman Wagh on March 26, 2008 and is headquartered in Mumbai, India.
Stock News
Supriya Lifescience Ltd me recent price jump ka main reason koi ek bada breaking news nahi hai, balki multiple factors ka combination hai. Company ne recently independent directors appointment approve kiya, jisse corporate governance strong hota dikha. Saath hi, market me Q4 results ko le kar strong expectations build ho rahi hain, jahan revenue aur profit growth ka estimate positive hai. Iske alawa, company ka expansion plan aur global growth focus bhi long-term sentiment ko support kar raha hai. 👉 Overall, yeh move news-driven kam aur expectation + momentum driven zyada hai.
Observation
If you see the on monthly Time frame you will see open marabuzu candle with bullish cross over on daytime frame on day Tf huge RSI breakout with very Good Volume stock also trade above 20 EMA on all Time frame.
Fundamentals Overview
| Parameter | Status | Interpretation |
|---|---|---|
| Revenue Growth | 📈 Strong | API demand stable |
| Margins | 👍 High (~38%) | Cost control strong |
| Profitability | 📈 Improving | Business gradually better ho raha hai |
| Valuation | 💰 Moderate | Na bahut sasta, na bahut mehenga |
| Market Trend | 🟡 Mixed | Long-term pressure, short-term bounce |
Technical Analysis & indicators 🔍
Weekly Chart
Bullish Cross Over
Rounding Bottom Breakout
News of the day
Reported Standalone quarterly numbers for Reliance Industries are:Net Sales at Rs 141,823.00 crore in March 2026 up 6.66% from Rs. 132,962.00 crore in March 2025.Quarterly Net Profit at Rs. 7,422.00 crore in March 2026 down 33.83% from Rs. 11,217.00 crore in March 2025.EBITDA stands at Rs. 15,319.00 crore in March 2026 down 25.97% from Rs. 20,693.00 crore in March 2025.Reliance EPS has decreased to Rs. 5.48 in March 2026 from Rs. 8.29 in March 2025.Reliance shares closed at 1,327.80 on April 23, 2026 (NSE) and has given -8.53% returns over the last 6 months and 2.01% over the last 12 months.
Sunpharma acquisition will create a top 25 global pharma company with a strong presence in women's health, biosimilars, and innovative medicines, leveraging Organon's global footprint and Sun's execution capabilities. The $11.75B deal is expected to deliver $350M in cost synergies and be EPS accretive from year one.
Educational content 📖
This stock analysis is designed for educational purposes and should not be taken as financial advice. Please carry out your own research or consult with a financial advisor before investing.
{{DATE}}
Launch your Graphy